AMRN · Amarin Corp Plc\Uk
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 11, 2025; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Earnings (loss) per Ordinary Share: Basic - non-GAAP non-GAAP | $0 | Three months ended June 30, 2026 | — |
| Earnings (loss) per Ordinary Share: Diluted - non-GAAP non-GAAP | $0 | Three months ended June 30, 2026 | — |
| Net income (loss) for EPS1 - non-GAAP non-GAAP | $790K | Three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss for EPS1 - GAAP -7.65M
+2.1M Stock-based compensation expense
+40K Restructuring
+6.3M Litigation-Related Charges
+0K Licensing Agreement Fees
+0K ADS Ratio Change Fees
= Net income (loss) for EPS1 - non-GAAP 790K
|
|||
| cash and investments | $302.6M | as of December 31, 2025 | — |
| restructuring charges | $36.2M | full year 2025 | — |
| Countries with Recordati VAZKEPA partnership | 59 | FY 2025 | — |
| IPE prescriptions market share | 50% | Year-end 2025 | — |
| Q3 2025 cash balance | $287M | Q3 2025 | — |
| Regional access for eligible patients in Italy | 90% | Year-end 2025 | — |
| Restructuring OPEX savings target | $70M | FY 2025 | — |
| Year-end 2025 cash balance | $303M | Year-end 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMRN
this stock
Amarin Corp Plc\Uk
|
$295.09M | +0.1% | +39.2% | — | 2.5% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.3% | +44.7% | 39.5 | 0.7% |
|
JNJ
Johnson & Johnson
|
$640.48B | +29.5% | +6.0% | 30.9 | 0.9% |
|
ABBV
AbbVie Inc.
|
$451.46B | +11.8% | +8.6% | 72.2 | 1.0% |
|
MRK
Merck & Co., Inc.
|
$368.94B | +40.9% | +1.3% | 119.6 | 1.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 11, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMRN | -0.9% | -2.0% | -4.2% | -2.0% | +0.1% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -1.3% | -5.0% | -17.6% | -5.0% | -12.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.